|
|
| (16 intermediate revisions by the same user not shown) |
| Line 1: |
Line 1: |
| {| style="border: 2px solid #4479BA; align="left" | | {| class="wikitable" |
| ! style="width: 800px; background: #4479BA;"|{{fontcolor|#FFF|Most Common Grade ≥3 Non-Serious Adverse Events}}
| | |+ |
| ! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF|Remdesivir}}
| | ! colspan="2" | |
| ! style="width: 200px; background: #4479BA;"|{{fontcolor|#FFF|Placebo}} | |
| |- | | |- |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Anemia or decreased hemoglobin | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 43 (8%) | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 47 (9%)
| |
| |- | | |- |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Acute kidney injury, decreased eGFR or creatinine renal clearance, or increased blood creatinine | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 40 (7%) | | | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 38 (7%)
| |
| |- | | |- |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Pyrexia | | | colspan="2" | |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 27 (5%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 17 (3%)
| |
| |-
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Hyperglycemia or increased blood glucose
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 22 (4%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 17 (3%)
| |
| |-
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | Increased transaminases, including ALT and/or AST
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 22 (4%)
| |
| | style="padding: 0 5px; background: #F5F5F5; text-align: left;" | 31 (6%)
| |
| |- | | |- |
| | | colspan="2" | |
| |} | | |} |